Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
DRUG Quote, Financials, Valuation and Earnings
Last price:
$71.53
Seasonality move
:
-11.31%
Day range:
$69.15 - $76.20
52-week range:
$23.18 - $123.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.56x
Volume:
318.1K
Avg. volume:
139.1K
1-year change:
98.62%
Market cap:
$688.1M
Revenue:
--
EPS (TTM):
-$1.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-- | -$0.90 | -- | -215.33% | $168.55 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.5M | $0.08 | 16.03% | -30.17% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$754.8M | $1.00 | 3.04% | 4.71% | $88.87 |
|
LLY
Eli Lilly & Co.
|
$17.7B | $7.26 | 38.36% | 137.08% | $1,209.21 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
$71.72 | $168.55 | $688.1M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.32 | $31.85 | $3.8B | 9.79x | $0.00 | 0% | 3.54x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.73 | $449.32 | $43.3B | 144.78x | $0.00 | 0% | 11.75x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$57.24 | $88.87 | $11.2B | 32.13x | $0.00 | 0% | 3.43x |
|
LLY
Eli Lilly & Co.
|
$954.52 | $1,209.21 | $884.9B | 43.85x | $1.73 | 0.63% | 13.84x |
|
SVRA
Savara, Inc.
|
$5.58 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
0.12% | 1.286 | 0.01% | 56.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.204 | 4.56% | 0.71x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-$14.2K | -$4.9M | -29.47% | -29.53% | -- | -$4.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
Bright Minds Biosciences, Inc. vs. Competitors
-
Which has Higher Returns DRUG or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of 96.33%. Bright Minds Biosciences, Inc.'s return on equity of -29.53% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.70 $65.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About DRUG or ACAD?
Bright Minds Biosciences, Inc. has a consensus price target of $168.55, signalling upside risk potential of 135%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 42.7%. Given that Bright Minds Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is DRUG or ACAD More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock DRUG or ACAD?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or ACAD?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Bright Minds Biosciences, Inc.'s net income of -$5.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$5.4M ACADACADIA Pharmaceuticals, Inc.3.54x 9.79x $284M $273.6M
-
Which has Higher Returns DRUG or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of 16.99%. Bright Minds Biosciences, Inc.'s return on equity of -29.53% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.70 $65.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About DRUG or ALNY?
Bright Minds Biosciences, Inc. has a consensus price target of $168.55, signalling upside risk potential of 135%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 36.68%. Given that Bright Minds Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is DRUG or ALNY More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock DRUG or ALNY?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or ALNY?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Bright Minds Biosciences, Inc.'s net income of -$5.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 144.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 11.75x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$5.4M ALNYAlnylam Pharmaceuticals, Inc.11.75x 144.78x $1.1B $186.4M
-
Which has Higher Returns DRUG or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -5.2%. Bright Minds Biosciences, Inc.'s return on equity of -29.53% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.70 $65.2M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About DRUG or BMRN?
Bright Minds Biosciences, Inc. has a consensus price target of $168.55, signalling upside risk potential of 135%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 55.26%. Given that Bright Minds Biosciences, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is DRUG or BMRN More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock DRUG or BMRN?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or BMRN?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Bright Minds Biosciences, Inc.'s net income of -$5.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 32.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 3.43x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$5.4M BMRNBioMarin Pharmaceutical, Inc.3.43x 32.13x $895M -$46.6M
-
Which has Higher Returns DRUG or LLY?
Eli Lilly & Co. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of 34.4%. Bright Minds Biosciences, Inc.'s return on equity of -29.53% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.70 $65.2M LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About DRUG or LLY?
Bright Minds Biosciences, Inc. has a consensus price target of $168.55, signalling upside risk potential of 135%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 26.68%. Given that Bright Minds Biosciences, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Bright Minds Biosciences, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 LLYEli Lilly & Co.18 6 1 -
Is DRUG or LLY More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.
-
Which is a Better Dividend Stock DRUG or LLY?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.63% to investors and pays a quarterly dividend of $1.73 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DRUG or LLY?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Bright Minds Biosciences, Inc.'s net income of -$5.4M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 43.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 13.84x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$5.4M LLYEli Lilly & Co.13.84x 43.85x $19.3B $6.6B
-
Which has Higher Returns DRUG or SVRA?
Savara, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -29.53% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.70 $65.2M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About DRUG or SVRA?
Bright Minds Biosciences, Inc. has a consensus price target of $168.55, signalling upside risk potential of 135%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.77%. Given that Bright Minds Biosciences, Inc. has higher upside potential than Savara, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 SVRASavara, Inc.6 0 0 -
Is DRUG or SVRA More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock DRUG or SVRA?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or SVRA?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$5.4M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$5.4M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
60
SNSE alert for Apr 2
Sensei Biotherapeutics, Inc. [SNSE] is up 11.23% over the past day.
Sell
47
TAYD alert for Apr 2
Taylor Devices, Inc. [TAYD] is up 1.04% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is down 17.29% over the past day.
